Literature DB >> 35839126

LEGO-Lipophosphonoxins: A Novel Approach in Designing Membrane Targeting Antimicrobials.

Duy Dinh Do Pham1, Viktor Mojr1, Michaela Helusová2, Gabriela Mikušová1,2, Radek Pohl1, Eva Dávidová1, Hana Šanderová3, Dragana Vítovská3, Kateřina Bogdanová4, Renata Večeřová4, Miroslava Htoutou Sedláková4, Radovan Fišer2, Petra Sudzinová3, Jiří Pospíšil3, Oldřich Benada3, Tomáš Křížek5, Adéla Galandáková6, Milan Kolář4, Libor Krásný3, Dominik Rejman1.   

Abstract

The alarming rise of bacterial antibiotic resistance requires the development of new compounds. Such compounds, lipophosphonoxins (LPPOs), were previously reported to be active against numerous bacterial species, but serum albumins abolished their activity. Here we describe the synthesis and evaluation of novel antibacterial compounds termed LEGO-LPPOs, loosely based on LPPOs, consisting of a central linker module with two attached connector modules on either side. The connector modules are then decorated with polar and hydrophobic modules. We performed an extensive structure-activity relationship study by varying the length of the linker and hydrophobic modules. The best compounds were active against both Gram-negative and Gram-positive species including multiresistant strains and persisters. LEGO-LPPOs act by first depleting the membrane potential and then creating pores in the cytoplasmic membrane. Importantly, their efficacy is not affected by the presence of serum albumins. Low cytotoxicity and low propensity for resistance development demonstrate their potential for therapeutic use.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35839126      PMCID: PMC9580004          DOI: 10.1021/acs.jmedchem.2c00684

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   8.039


  43 in total

Review 1.  Viability states of bacteria--specific mechanisms of selected probes.

Authors:  Heike Sträuber; Susann Müller
Journal:  Cytometry A       Date:  2010-07       Impact factor: 4.355

Review 2.  Natural products as sources of new drugs over the last 25 years.

Authors:  David J Newman; Gordon M Cragg
Journal:  J Nat Prod       Date:  2007-02-20       Impact factor: 4.050

3.  Antimicrobial activities of ceragenins against clinical isolates of resistant Staphylococcus aureus.

Authors:  Judy N Chin; Michael J Rybak; Chrissy M Cheung; Paul B Savage
Journal:  Antimicrob Agents Chemother       Date:  2007-01-08       Impact factor: 5.191

4.  Fatty Acid Comprising Lysine Conjugates: Anti-MRSA Agents That Display In Vivo Efficacy by Disrupting Biofilms with No Resistance Development.

Authors:  Mohini M Konai; Jayanta Haldar
Journal:  Bioconjug Chem       Date:  2017-03-06       Impact factor: 4.774

Review 5.  De novo designed synthetic mimics of antimicrobial peptides.

Authors:  Richard W Scott; William F DeGrado; Gregory N Tew
Journal:  Curr Opin Biotechnol       Date:  2008-11-17       Impact factor: 9.740

6.  Bactericidal Activity of Ceragenin CSA-13 in Cell Culture and in an Animal Model of Peritoneal Infection.

Authors:  Robert Bucki; Katarzyna Niemirowicz; Urszula Wnorowska; Fitzroy J Byfield; Ewelina Piktel; Marzena Wątek; Paul A Janmey; Paul B Savage
Journal:  Antimicrob Agents Chemother       Date:  2015-07-27       Impact factor: 5.191

7.  A comparative study on the cost of new antibiotics and drugs of other therapeutic categories.

Authors:  Matthew E Falagas; Konstantinos N Fragoulis; Ioannis Karydis
Journal:  PLoS One       Date:  2006-12-20       Impact factor: 3.240

8.  Generation of Persister Cells of Pseudomonas aeruginosa and Staphylococcus aureus by Chemical Treatment and Evaluation of Their Susceptibility to Membrane-Targeting Agents.

Authors:  Lucia Grassi; Mariagrazia Di Luca; Giuseppantonio Maisetta; Andrea C Rinaldi; Semih Esin; Andrej Trampuz; Giovanna Batoni
Journal:  Front Microbiol       Date:  2017-10-04       Impact factor: 5.640

Review 9.  Antibiotics in the clinical pipeline in October 2019.

Authors:  Mark S Butler; David L Paterson
Journal:  J Antibiot (Tokyo)       Date:  2020-03-10       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.